An open-label study was carried out in 2016 in the UK to analyze the feasibility, safety and efficacy of psilocybin in treating people with unipolar treatment-resistant depression with promising effects; Even though the study was smaller and included only twelve individuals, seven of All those people fulfilled formal criteria for remission one part